Kissei Pharmaceutical Co., Ltd. and Eisai Company, Ltd. Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries

Published: Jun 12, 2007

Tokyo, June 12, 2007 (JCN Newswire) - Kissei Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced the conclusion of a license agreement for Glufast(R) (tablets, generic name: mitiglinide calcium hydrate), a rapid-acting insulin secretagogue originally created and developed by Kissei. In this agreement, Eisai gained the exclusive development and commercialization rights of Glufast(R) in a total of 10 ASEAN countries from Kissei.

Back to news